Published in AIDS Weekly, July 8th, 1996
New data on its first clinical compound, GEM 91, a planned Investigational New Drug (IND) filing for a compound targeted at cytomegalovirus (CMV) disease, and the first commercial-scale manufacturing of synthetic DNA.
The highlight of the 1996 midyear progress report was the announcement that Hybridon has planned to start clinical trials in Europe in the Summer 1996 of GEM 132, a genetic antisense compound for patients with CMV disease. This trial involves systemic administration of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.